| Schmieder, Roland E |
| Completed | 4 | 105 | Europe | Evolocumab Prefilled Syringe, Placebos | University of Erlangen-Nürnberg Medical School | Atherosclerotic Cardiovascular Disease | 04/21 | 07/21 | | |
NCT06560801: Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation |
|
|
| Recruiting | 4 | 48 | Europe | Dapagliflozin 10mg Tab | University of Erlangen-Nürnberg Medical School | Chronic Kidney Diseases | 10/26 | 12/26 | | |
SEMA, NCT05303857: Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 90 | Europe | Semaglutide Pen Injector, Placebo | University of Erlangen-Nürnberg Medical School | Diabetes Mellitus, Type 2 | 12/23 | 12/24 | | |
| Recruiting | 3 | 75 | Europe | Finerenone 20 MG Oral Tablet, Placebo | University of Erlangen-Nürnberg Medical School, Bayer | Type2diabetes | 06/25 | 12/25 | | |
NCT04321044: Genetic Based Analysis in Hypertensive Patients |
|
|
| Active, not recruiting | N/A | 300 | Europe | Genetic based analysis of identifying predictors of blood pressure in patients after renal denervation | University of Erlangen-Nürnberg Medical School | Hypertension, Renal Denervation, Genetic Predisposition | 07/20 | 12/23 | | |
| Active, not recruiting | N/A | 44 | Europe | Renal denervation | University of Erlangen-Nürnberg Medical School | Uncontrolled Hypertension, Renal Denervation, Chronic Kidney Disease stage3 | 12/23 | 12/23 | | |
NCT06056466: Different Vascular and Renal Parameters in Living Kidney Donors |
|
|
| Completed | N/A | 25 | Europe | | University of Erlangen-Nürnberg Medical School | Renal Injury | 11/23 | 02/24 | | |
NCT05198674: SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN |
|
|
| Recruiting | N/A | 1400 | Europe, US, RoW | Renal Denervation (Symplicity Spyral™), Renal Angiography, Renal Denervation | Medtronic Vascular | Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus | 11/26 | 11/29 | | |
NCT06051812: Proteinuria and Renal Perfusion in Renal Transplant Recipients |
|
|
| Recruiting | N/A | 25 | Europe | | University of Erlangen-Nürnberg Medical School | Pre-kidney Transplant, Living Donor Kidney Transplantation, Renal Perfusion, End Stage Renal Disease | 03/25 | 03/26 | | |
ISTHA, NCT05903586: Vascular Changes in Patients With Aotic Isthmus Stenosis After Interventional Therapy |
|
|
| Recruiting | N/A | 16 | Europe | | University of Erlangen-Nürnberg Medical School | Aortic Isthmus Stenosis | 02/25 | 04/25 | | |
| Active, not recruiting | N/A | 44 | Europe | Renal denervation | University of Erlangen-Nürnberg Medical School | Uncontrolled Hypertension, Autosomal Dominant Polycystic Kidney Disease, Renal Denervation | 03/28 | 03/28 | | |
| Fietkau, Rainer |
| Completed | 3 | 830 | Europe | Induction chemotherapy with gemcitabine or FOLFIRINOX, all brands of gemcitabine and FOLFIRINOX components are allowed, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine, all brands of gemcitabine are allowed, Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy | University of Erlangen-Nürnberg Medical School | Pancreatic Cancer | 02/21 | 11/23 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients |
|
|
| Active, not recruiting | 3 | 702 | Europe | Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin | Prof. Dr. med. Claus Rödel | Rectal Cancer Stage III | 09/23 | 09/28 | | |
NCT03697343: Fractionated Stereotactic Radiotherapy vs. Single Session Radiosurgery in Patients With Larger Brain Metastases |
|
|
| Recruiting | 3 | 382 | Europe | Radiosurgery, Fractionated stereotactic radiotherapy | University of Erlangen-Nürnberg Medical School | Cerebral Metastases of Solid Cancers | 05/26 | 05/26 | | |
DIREKHT2, NCT06030440: De-Intensification of Postoperative Radiotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck |
|
|
| Recruiting | 2/3 | 508 | Europe | Eliminating RT to the elective neck, RT standard of care | University of Erlangen-Nürnberg Medical School | Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Hypopharynx, Squamous Cell Carcinoma of the Oropharynx | 12/31 | 09/33 | | |
FOKAL-BT, NCT02391051: Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial |
|
|
| Recruiting | 2 | 50 | Europe | HDR-Brachytherapy | University of Erlangen-Nürnberg Medical School | Prostate Cancer | 12/19 | 12/29 | | |
| Completed | 2 | 120 | Europe | Durvalumab + Tremelimumab + RT | University of Erlangen-Nürnberg Medical School | Locally Advanced Head and Neck Squamous Cell Carcinoma | 09/21 | 02/24 | | |
| Active, not recruiting | 2 | 120 | Europe | Trabectedin, Yondelis, DNA double-strand breaks | Ludwig-Maximilians - University of Munich | Sarcoma | 08/23 | 08/23 | | |
| Completed | 2 | 115 | Europe | A (pembrolizumab+RT), Keytruda + RT, B (pembrolizumab), Keytruda | University of Erlangen-Nürnberg Medical School, Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg | Head and Neck Squamous Cell Carcinoma | 10/24 | 10/24 | | |
NCT05433116: Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC |
|
|
| Recruiting | 2 | 50 | Europe | Pembrolizumab, Keytruda, Lenvatinib, Lenvima | Universität des Saarlandes | Head and Neck Squamous Cell Carcinoma | 09/25 | 09/26 | | |
HyRec, NCT01716949: Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer |
|
|
| Recruiting | 1/2 | 59 | Europe | Radiotherapy, Hyperthermia, 5-Fluorouracil, all brands of 5-Fluorouracil are allowed, Capecitabine, all brands of Capecitabine are allowed, Oxaliplatin, all brands of oxaliplatin are allowed | University of Erlangen-Nürnberg Medical School | Rectal Cancer | 06/22 | 06/23 | | |
ST-ICI, NCT03453892: Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition |
|
|
| Completed | N/A | 150 | Europe | Nivolumab, Pembrolizumab, Radiotherapy, Ipilimumab | University of Erlangen-Nürnberg Medical School | Metastatic Cancer | 02/21 | 12/22 | | |
NCT02022384: Immunophenotyping From Blood of Patients With Malignant Gliomas |
|
|
| Completed | N/A | 50 | Europe | Blood sample and life quality questionnaires | University of Erlangen-Nürnberg Medical School | Anaplastic Astrocytoma, Glioblastoma Multiforme | 12/21 | 12/22 | | |
GLIO-CMV-01, NCT02600065: Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy |
|
|
| Completed | N/A | 350 | Europe | Blood draw and MRI | University of Erlangen-Nürnberg Medical School | Cytomegalovirus Infections | 12/22 | 12/22 | | |
| Recruiting | N/A | 500 | Europe | TTFields | NovoCure Ltd. | Glioblastoma | 12/24 | 02/25 | | |
ST-ICI02, NCT04892849: Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy |
|
|
| Recruiting | N/A | 200 | Europe | Conventional Therapy acc. to prevailing clincal approved schemes | University of Erlangen-Nürnberg Medical School | HNSCC, NSCLC, Esophageal Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Skin, Small Cell Bronchial Carcinomas | 05/26 | 12/27 | | |
IMMO-LDRT02, NCT05887284: Investigation of the Clinical Efficacy of Low-dose Ionizing Radiation in the Treatment of Osteoarthritis |
|
|
| Recruiting | N/A | 132 | Europe | low dose radiotherapy (0.5 Gy), mock radiation treatment, low dose radiotherapy (1.0 Gy) | University of Erlangen-Nürnberg Medical School, Johann Wolfgang Goethe University Hospital | Arthrosis, Osteoarthritis | 09/26 | 12/28 | | |
| Ott, Christian |
| Active, not recruiting | N/A | 44 | Europe | Renal denervation | University of Erlangen-Nürnberg Medical School | Uncontrolled Hypertension, Renal Denervation, Chronic Kidney Disease stage3 | 12/23 | 12/23 | | |
| Achenbach, Stephan |
NCT06404437: Detection of Aortic Stenosis With Smartphone Auscultation Using Machine Learning (HEARTBEAT-Pilot) |
|
|
| Recruiting | N/A | 100 | Europe | Auscultation | Friedrich-Alexander-Universität Erlangen-Nürnberg, University of Erlangen-Nürnberg Medical School | Aortic Valve Stenosis | 07/24 | 10/24 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
OPTICO-LM, NCT03820492: Comparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT |
|
|
| Recruiting | N/A | 104 | Europe, Japan | OCT, FFR, CTA and FFRCT | University Hospital Inselspital, Berne | Coronary Stenosis | 12/26 | 12/26 | | |
| Recruiting | N/A | 3390 | Europe | Culprit-lesion revascularization, Culprit-lesion PCI, Non-culprit-lesion revascularization, multivessel PCI | Leipzig Heart Science gGmbH, Heart Center Leipzig at University of Leipzig, German Federal Ministry of Education and Research, IHF GmbH - Institut für Herzinfarktforschung, Stiftung IHF - Institut für Herzinfarktforschung | Non-ST-elevation Myocardial Infarction, Multivessel Coronary Artery Disease | 01/27 | 07/27 | | |
| Hueber, Axel |
| Completed | N/A | 503 | Europe | Questionnaire | University of Oxford, Amgen | Psoriatic Arthritis | 03/22 | 03/22 | | |
| Wagner, Nicola |
| Recruiting | 2/3 | 463 | Europe, US, RoW | Elenestinib, BLU-263, Placebo | Blueprint Medicines Corporation | Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis | 06/28 | 06/28 | | |
| Winkler, Jürgen |
| Recruiting | N/A | 392 | Europe | Ultra-high-caloric fatty diet, Placebo | University of Ulm | Amyotrophic Lateral Sclerosis | 06/27 | 06/27 | | |
HSP-PBP, NCT03981276: Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders |
|
|
| Recruiting | N/A | 2000 | Europe | Clinical rating scale to measure disease severity and progression, Spastic Paraplegia Rating Scale (SPRS), Next-Gen Sequencing (NGS) | Dr. Rebecca Schule, German Federal Ministry of Education and Research, German Center for Neurodegenerative Diseases (DZNE) | Hereditary Spastic Paraplegia | 08/39 | 08/41 | | |
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort |
|
|
| Recruiting | N/A | 35000 | Europe, Canada, US, RoW | | CHDI Foundation, Inc. | Huntington's Disease | 01/62 | 01/62 | | |
| Koch, Jan C |
| Recruiting | N/A | 3000 | Europe | Neurofilament light chain | Charite University, Berlin, Germany, Boris Canessa ALS Stiftung | Amyotrophic Lateral Sclerosis, Motor Neuron Disease | 12/24 | 12/24 | | |
| Recruiting | N/A | 392 | Europe | Ultra-high-caloric fatty diet, Placebo | University of Ulm | Amyotrophic Lateral Sclerosis | 06/27 | 06/27 | | |
| Kannenkeril, Dennis |
NCT06560801: Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation |
|
|
| Recruiting | 4 | 48 | Europe | Dapagliflozin 10mg Tab | University of Erlangen-Nürnberg Medical School | Chronic Kidney Diseases | 10/26 | 12/26 | | |
| Recruiting | 3 | 75 | Europe | Finerenone 20 MG Oral Tablet, Placebo | University of Erlangen-Nürnberg Medical School, Bayer | Type2diabetes | 06/25 | 12/25 | | |
NCT06056466: Different Vascular and Renal Parameters in Living Kidney Donors |
|
|
| Completed | N/A | 25 | Europe | | University of Erlangen-Nürnberg Medical School | Renal Injury | 11/23 | 02/24 | | |
NCT06051812: Proteinuria and Renal Perfusion in Renal Transplant Recipients |
|
|
| Recruiting | N/A | 25 | Europe | | University of Erlangen-Nürnberg Medical School | Pre-kidney Transplant, Living Donor Kidney Transplantation, Renal Perfusion, End Stage Renal Disease | 03/25 | 03/26 | | |
ISTHA, NCT05903586: Vascular Changes in Patients With Aotic Isthmus Stenosis After Interventional Therapy |
|
|
| Recruiting | N/A | 16 | Europe | | University of Erlangen-Nürnberg Medical School | Aortic Isthmus Stenosis | 02/25 | 04/25 | | |
| Gaede, Luise |
EXAMINE-CAD, NCT05294887: Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease |
|
|
| Recruiting | 4 | 132 | Europe | Bisoprolol, beta blocker, Diltiazem, Placebo | Charite University, Berlin, Germany, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) | Coronary Microvascular Dysfunction, Microvascular Angina, Vasospasm, Coronary, Vasospastic Angina, Prinzmetal Angina, Coronary Artery Disease | 06/24 | 06/24 | | |
| Recruiting | N/A | 1054 | Europe | measurement of FFR, measurement of Pd/Pa | Helios Health Institute GmbH, Heart Center Leipzig - University Hospital | Coronary Artery Disease, Coronary Artery Stenoses | 05/26 | 11/26 | | |
| Bohr, Daniela |
| Recruiting | 1/2 | 24 | Europe | anti-CD19 CAR T cell therapy | University of Erlangen-Nürnberg Medical School | Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis, Polymyositis | 05/26 | 05/26 | | |
| Recruiting | N/A | 606 | Europe | Treat-to-target as a new treatment concept | Heinrich-Heine University, Duesseldorf, University Hospital Heidelberg, German Diabetes-Center, Leibniz-Institut in Düsseldorf, Lupus Erythematodes-Selbsthilfegemeinschaft e.V. | Systemic Lupus Erythematosus | 04/26 | 09/26 | | |
| Grieshaber-Bouyer, Ricardo |
| Recruiting | N/A | 606 | Europe | Treat-to-target as a new treatment concept | Heinrich-Heine University, Duesseldorf, University Hospital Heidelberg, German Diabetes-Center, Leibniz-Institut in Düsseldorf, Lupus Erythematodes-Selbsthilfegemeinschaft e.V. | Systemic Lupus Erythematosus | 04/26 | 09/26 | | |
